This technology identifies a key pathway involved in the development of malignant cells associated with multiple myeloma and demonstrates that its inhibition is a promising strategy for treating the disease.
Current treatments for multiple myeloma rely on immunomodulatory therapies. However, these types of treatments show low success rates for individuals with refractory or relapsed conditions, and there is currently no effective treatment for these two forms of the disease.
This technology identifies a cell signaling pathway that can be inhibited to reduce the aberrant growth of B and plasma cells, which are the underlying cell mutations of multiple myeloma. This approach has been shown to effectively reduce proliferation in cell lines that are resistant to immunomodulatory drugs and can be effective in conventional as well as refractory and relapsed cases of multiple myeloma. Moreover, several small molecule inhibitors for this pathway have already been identified. This technology provides a promising approach that targets the underlying cause of multiple myeloma and may be effective in various forms of the condition, including refractory and relapsed cases.
Patent Pending
IR CU17162
Licensing Contact: Jerry Kokoshka